J. Stuart Elborn J. Stuart Elborn is Dean of the School of Medicine, Dentistry and Biomedical Sciences (SMDBS), Queen’s University Belfast, Belfast, UK. He was previously director of the Centre for Infection and Immunity in SMDBS and Professor of Respiratory Medicine. He is a consultant physician in Belfast City Hospital (Belfast, UK), where he started an adult CF programme that now has 300 patients, and he collaborates closely with his paediatric colleagues who provide care for 180 patients. Additionally, he is president of the ECFS and is a trustee of the UK CF Trust. Stuart Elborn has led a number of clinical trials involving antibiotics, anti-inflammatory agents and cystic fibrosis trans- membrane conductance regulator (CFTR)-modulating drugs. He also leads a clinical trials programme in bronchiectasis. His team of pulmonary researchers has recently been selected as part of a Translational Research Partnership in the UK, which focuses on academics working with the pharmaceutical industry in pre- clinical and early clinical trials. His group is also part of the ECFS Clinical Trials Network. He is principal investigator on a number of early stage anti-inflammatory and potentially disease-modify- ing therapies in CF and other lung diseases. Stuart Elborn has a major clinical and laboratory research programme in airways infection, funded jointly by the National Institutes of Health (Bethesda, MD, USA), the Research and Development Office in Northern Ireland, the UK Medical Research Council, the Science Foundation Ireland and the European Union Framework 7, investigating the clinical implica- tions of bacterial diversity and, in particular, anaerobes in the CF airway. This involves clinical research and also a range of projects investigating the interaction between bacteria and the host innate immunity. xii